MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of “40 years of wilderness” and into a clear path of regulatory approval

Những quyển sách tương tự

• A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
  Bằng: Hu Y, et al.
  Được phát hành: (2025-10-01)
• P-038 MET activation via exon 14 skipping mutations (METex14del): gastrointestinal prevalence and sensitivity to MET inhibitor AMG337
  Bằng: Cecchi, F., et al.
  Được phát hành: (2016)
• Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
  Bằng: Drilon, Alexander, et al.
  Được phát hành: (2016)
• Gastrointestinal malignancies harbor actionable MET exon 14 deletions
  Bằng: Lee, Jeeyun, et al.
  Được phát hành: (2015)
• MET exon 14-altered lung cancers and MET inhibitor resistance
  Bằng: Guo, Robin, et al.
  Được phát hành: (2020)